Pacira | PCRX - Gross Profit On Sales


Pacira reported $126.64M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Assertio Holdings USD 22.24M 970K Jun/2024
Astellas Pharma JPY 444.26B 12.55B Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Coherus Biosciences USD 8.7M 853K Dec/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
J&J USD 17.24B 642M Mar/2026
Ligand Pharmaceuticals USD 48.45M 8.22M Mar/2026
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Omeros USD -33.16M 18.52M Jun/2024
Pacira USD 126.64M 15.61M Mar/2026
Perrigo USD 325.5M 36.7M Mar/2026
Pfizer USD 11.04B 1.24B Mar/2026
Supernus Pharmaceuticals USD 129.36M 34.68M Mar/2026
Teva Pharmaceutical Industries USD 2.11B 547M Mar/2026
Xeris Pharmaceuticals USD 72.15M 8.77M Dec/2025
Xoma 992K 846K Jun/2024
Zoetis USD 1.62B 20M Mar/2026